GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jubilant Pharmova Ltd (BOM:530019) » Definitions » Debt-to-Revenue

Jubilant Pharmova (BOM:530019) Debt-to-Revenue : 0.53 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Jubilant Pharmova Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Jubilant Pharmova's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹2,991 Mil. Jubilant Pharmova's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹33,649 Mil. Jubilant Pharmova's annualized Revenue for the quarter that ended in Mar. 2024 was ₹69,856 Mil. Jubilant Pharmova's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.52.


Jubilant Pharmova Debt-to-Revenue Historical Data

The historical data trend for Jubilant Pharmova's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jubilant Pharmova Debt-to-Revenue Chart

Jubilant Pharmova Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 0.47 0.53 0.59 0.55

Jubilant Pharmova Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 - 0.55 - 0.53

Competitive Comparison of Jubilant Pharmova's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jubilant Pharmova's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Jubilant Pharmova's Debt-to-Revenue falls into.



Jubilant Pharmova Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Jubilant Pharmova's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2991 + 33649) / 66448
=0.55

Jubilant Pharmova's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2991 + 33649) / 69856
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Jubilant Pharmova Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Jubilant Pharmova's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Jubilant Pharmova (BOM:530019) Business Description

Traded in Other Exchanges
Address
1A, Sector 16A, Noida, UP, IND, 201 301
Jubilant Pharmova Ltd is an integrated global pharmaceutical company. The company's segment includes Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment. Geographically, it derives a majority of its revenue from Americas and Europe.

Jubilant Pharmova (BOM:530019) Headlines

No Headlines